
Tianjin Medical Journal ›› 2025, Vol. 53 ›› Issue (11): 1145-1151.doi: 10.11958/20251448
• Clinical Research • Previous Articles Next Articles
ZHENG Tongtong1(
), WANG Min2, SHAN Qi3, LI Minghang3, BAI Yazhen4, FU Qizhi3△(
)
Received:2025-04-18
Revised:2025-08-10
Published:2025-11-15
Online:2025-11-19
Contact:
△E-mail:ZHENG Tongtong, WANG Min, SHAN Qi, LI Minghang, BAI Yazhen, FU Qizhi. Analysis of microbial community composition of lower respiratory tract in patients with severe hospital-acquired pneumonia in critical care[J]. Tianjin Medical Journal, 2025, 53(11): 1145-1151.
CLC Number:
| 组别 | n | Shannon指数 | Simpson指数 | Richness指数 | Chao1指数 | |
|---|---|---|---|---|---|---|
| 青年组 | 7 | 1.57(1.52,1.71) | 0.70(0.68,0.73) | 14.00(12.00,14.50) | 14.00(12.50,14.75) | |
| 中年组 | 12 | 0.58(0.29,0.85)a | 0.29(0.10,0.51)a | 11.50(9.75,12.50) | 12.00(9.88,16.25) | |
| 老年组 | 65 | 1.21(0.71,1.74)b | 0.58(0.30,0.77) | 12.00(11.00,13.00) | 12.50(11.00,14.00) | |
| H | 6.791* | 5.208* | 2.113 | 0.687 | ||
| 非吸烟组 | 70 | 1.13(0.62,1.70) | 0.57(0.29,0.75) | 12.00(11.00,13.00) | 12.75(11.00,14.00) | |
| 吸烟组 | 14 | 1.19(0.56,1.71) | 0.61(0.25,0.72) | 12.00(9.25,14.75) | 12.50(9.25,15.00) | |
| U | 459.000 | 448.000 | 473.000 | 485.000 | ||
| 无脑卒中组 | 59 | 1.51(0.75,1.77) | 0.66(0.35,0.77) | 12.00(10.00,14.00) | 13.00(11.00,15.00) | |
| 合并脑卒中组 | 25 | 0.72(0.48,1.26) | 0.36(0.22.0.64) | 12.00(11.00,13.00) | 12.00(11.00,14.00) | |
| U | 518.000* | 509.000* | 701.000 | 645.000 | ||
| 无糖尿病组 | 47 | 1.53(0.58,1.77) | 0.69(0.29,0.78) | 12.00(11.00,13.00) | 12.33(11.00,15.00) | |
| 合并糖尿病组 | 37 | 1.04(0.60,1.54) | 0.43(0.28,0.72) | 12.00(10.00,14.00) | 13.00(11.00,14.00) | |
| U | 723.000 | 728.000 | 923.500 | 860.500 | ||
| 无慢性肺病组 | 62 | 1.23(0.58,1.77) | 0.61(0.29,0.77) | 12.00(10.25,13.75) | 12.00(11.00,14.00) | |
| 合并慢性肺病组 | 22 | 1.00(0.71,1.52) | 0.50(0.29,0.71) | 12.00(10.25,13.75) | 13.25(12.00,15.00) | |
| U | 584.000 | 595.000 | 678.000 | 822.000 | ||
| 未行人工气道治疗组 | 28 | 1.60(1.13,1.99) | 0.71(0.53,0.82) | 13.00(12.00,15.00) | 14.00(13.00,15.00) | |
| 人工气道治疗≤3 d组 | 34 | 1.16(0.44,1.70)c | 0.54(0.18,0.77)c | 11.00(9.00,12.00)c | 12.00(10.00,13.00)c | |
| 人工气道治疗>3 d组 | 22 | 0.72(0.25,1.03)cd | 0.37(0.10,0.55)cd | 12.00(10.25,12.75)cd | 12.00(10.25,14.75) | |
| H | 17.568** | 14.504** | 11.401** | 10.193** | ||
Tab.1 Comparison of lower respiratory tract microbial diversity between different groups of patients
| 组别 | n | Shannon指数 | Simpson指数 | Richness指数 | Chao1指数 | |
|---|---|---|---|---|---|---|
| 青年组 | 7 | 1.57(1.52,1.71) | 0.70(0.68,0.73) | 14.00(12.00,14.50) | 14.00(12.50,14.75) | |
| 中年组 | 12 | 0.58(0.29,0.85)a | 0.29(0.10,0.51)a | 11.50(9.75,12.50) | 12.00(9.88,16.25) | |
| 老年组 | 65 | 1.21(0.71,1.74)b | 0.58(0.30,0.77) | 12.00(11.00,13.00) | 12.50(11.00,14.00) | |
| H | 6.791* | 5.208* | 2.113 | 0.687 | ||
| 非吸烟组 | 70 | 1.13(0.62,1.70) | 0.57(0.29,0.75) | 12.00(11.00,13.00) | 12.75(11.00,14.00) | |
| 吸烟组 | 14 | 1.19(0.56,1.71) | 0.61(0.25,0.72) | 12.00(9.25,14.75) | 12.50(9.25,15.00) | |
| U | 459.000 | 448.000 | 473.000 | 485.000 | ||
| 无脑卒中组 | 59 | 1.51(0.75,1.77) | 0.66(0.35,0.77) | 12.00(10.00,14.00) | 13.00(11.00,15.00) | |
| 合并脑卒中组 | 25 | 0.72(0.48,1.26) | 0.36(0.22.0.64) | 12.00(11.00,13.00) | 12.00(11.00,14.00) | |
| U | 518.000* | 509.000* | 701.000 | 645.000 | ||
| 无糖尿病组 | 47 | 1.53(0.58,1.77) | 0.69(0.29,0.78) | 12.00(11.00,13.00) | 12.33(11.00,15.00) | |
| 合并糖尿病组 | 37 | 1.04(0.60,1.54) | 0.43(0.28,0.72) | 12.00(10.00,14.00) | 13.00(11.00,14.00) | |
| U | 723.000 | 728.000 | 923.500 | 860.500 | ||
| 无慢性肺病组 | 62 | 1.23(0.58,1.77) | 0.61(0.29,0.77) | 12.00(10.25,13.75) | 12.00(11.00,14.00) | |
| 合并慢性肺病组 | 22 | 1.00(0.71,1.52) | 0.50(0.29,0.71) | 12.00(10.25,13.75) | 13.25(12.00,15.00) | |
| U | 584.000 | 595.000 | 678.000 | 822.000 | ||
| 未行人工气道治疗组 | 28 | 1.60(1.13,1.99) | 0.71(0.53,0.82) | 13.00(12.00,15.00) | 14.00(13.00,15.00) | |
| 人工气道治疗≤3 d组 | 34 | 1.16(0.44,1.70)c | 0.54(0.18,0.77)c | 11.00(9.00,12.00)c | 12.00(10.00,13.00)c | |
| 人工气道治疗>3 d组 | 22 | 0.72(0.25,1.03)cd | 0.37(0.10,0.55)cd | 12.00(10.25,12.75)cd | 12.00(10.25,14.75) | |
| H | 17.568** | 14.504** | 11.401** | 10.193** | ||
Fig.3 Microbial analysis of the differences between the group without artificial airway treatment and the group with artificial airway treatment for more than 3 days
Fig.4 Microbial analysis of the differences between the group treated with artificial airway for ≤ 3 days and the group treated with artificial airway for > 3 days
| [1] | GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9. |
| [2] | KALIL A C, METERSKY M L, KLOMPAS M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016, 63(5):e61-e111. doi:10.1093/cid/ciw353. |
| [3] | TORRES A, NIEDERMAN M S, CHASTRE J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia(HAP)/ventilator-associated pneumonia(VAP)of the European Respiratory Society (ERS),European Society of Intensive Care Medicine(ESICM),European Society of Clinical Microbiology and Infectious Diseases(ESCMID)and Asociación Latinoamericana del Tórax(ALAT)[J]. Eur Respir J, 2017, 50(3):1700582. doi:10.1183/13993003.00582-2017. |
| [4] | MEHTA A B, SYEDA S N, WIENER R S, et al. Epidemiological trends in invasive mechanical ventilation in the United States: A population-based study[J]. J Crit Care, 2015, 30(6):1217-1221. doi:10.1016/j.jcrc.2015.07.007. |
| [5] | IBN SAIED W, MOURVILLIER B, COHEN Y, et al. A Comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia[J]. Crit Care Med, 2019, 47(3):345-352. doi:10.1097/CCM.0000000000003553. |
| [6] | 刘又宁, 曹彬, 王辉, 等. 中国九城市成人医院获得性肺炎微生物学与临床特点调查[J]. 中华结核和呼吸杂志, 2012, 35(10):739-746. |
| LIU Y N, CAO B, WANG H, et al. Microbiological and clinical features of hospital-acquired pneumonia in adults from nine cities of China[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2012, 35(10):739-746. doi:10.3760/cma.j.issn.1001-0939.2012.10.009. | |
| [7] | METLAY J P, WATERER G W, LONG A C, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America[J]. Am J Respir Crit Care Med, 2019, 200(7):e45-e67. doi:10.1164/rccm.201908-1581ST. |
| [8] | ZHOU Y, LIU M, YANG J. Recovering metagenome-assembled genomes from shotgun metagenomic sequencing data: Methods, applications, challenges, and opportunities[J]. Microbiol Res, 2022, 260:127023. doi:10.1016/j.micres.2022.127023. |
| [9] | JIN X, LI J, SHAO M, et al. Improving suspected pulmonary infection diagnosis by bronchoalveolar lavage fluid metagenomic next-generation sequencing:a multicenter retrospective study[J]. Microbiol Spectr, 2022, 10(4):e0247321. doi:10.1128/spectrum.02473-21. |
| [10] | XU J, ZHOU P, LIU J, et al. Utilizing metagenomic next-generation sequencing (mNGS) for rapid pathogen identification and to inform clinical decision-making:results from a large real-world cohort[J]. Infect Dis Ther, 2023, 12(4):1175-1187. doi:10.1007/s40121-023-00790-5. |
| [11] | 中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4):255-280. |
| Chinese Medical Association,Respiratory Medicine Branch,Infection Group. Diagnosis and treatment guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in Chinese adults (2018 Edition)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2018, 41(4):255-280. doi:10.3760/cma.j.issn.1001-0939.2018.04.006. | |
| [12] | DICKSON R P, ERB-DOWNWARD J R, FREEMAN C M, et al. Bacterial topography of the healthy human lower respiratory tract[J]. mBio, 2017, 8(1):e02287-1. doi:10.1128/mBio.02287-16. |
| [13] | MORRIS A, BECK J M, SCHLOSS P D, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers[J]. Am J Respir Crit Care Med, 2013, 187(10):1067-1075. doi:10.1164/rccm.201210-1913OC. |
| [14] | EINARSSON G G, COMER D M, MCILREAVEY L, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers[J]. Thorax, 2016, 71(9):795-803. doi:10.1136/thoraxjnl-2015-207235. |
| [15] | DURACK J, HUANG Y J, NARIYA S, et al. Bacterial biogeography of adult airways in atopic asthma[J]. Microbiome, 2018, 6(1):104. doi:10.1186/s40168-018-0487-3. |
| [16] | ZHU S F, WU X X, GUO Y, et al. A 16S rDNA sequencing-based analysis of airway microecology in patients with an acute exacerbation of chronic obstructive pulmonary disease: A cross-sectional study in Inner Mongolia, China[J]. Front Med (Lausanne), 2022, 9:946238. doi:10.3389/fmed.2022.946238. |
| [17] | BYUN M K, CHANG J, KIM H J, et al. Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis[J]. PLoS One, 2017, 12(8):e0183553. doi:10.1371/journal.pone.0183553. |
| [18] | GUAN W J, YUAN J J, LI H M, et al. Altered community compositions of Proteobacteria in adults with bronchiectasis[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13:2173-2182. doi:10.2147/COPD.S159335. |
| [19] | HAN M K, ZHOU Y, MURRAY S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study[J]. Lancet Respir Med, 2014, 2(7):548-556. doi:10.1016/S2213-2600(14)0069-4. |
| [20] | INVERNIZZI R, WU B G, BARNETT J, et al. The respiratory microbiome in chronic hypersensitivity pneumonitis is distinct from that of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2021, 203(3):339-347. doi:10.1164/rccm.202002-0460OC. |
| [21] | HUANG D, SU X, YUAN M, et al. The characterization of lung microbiome in lung cancer patients with different clinicopathology[J]. Am J Cancer Res, 2019, 9(9):2047-2063. |
| [22] | CHEN Y, FENG W, YE K, et al. Application of metagenomic next-generation sequencing in the diagnosis of pulmonary infectious pathogens from bronchoalveolar lavage samples[J]. Front Cell Infect Microbiol, 2021, 11:541092. doi:10.3389/fcimb.2021.541092. |
| [23] | MAN W H, DE STEENHUIJSEN PITERS W A, BOGAERT D. The microbiota of the respiratory tract: gatekeeper to respiratory health[J]. Nat Rev Microbiol, 2017, 15(5):259-270. doi:10.1038/nrmicro.2017.14. |
| [24] | SOLE M L, YOOSEPH S, TALBERT S, et al. Pulmonary Microbiome of Patients Receiving Mechanical Ventilation: Changes Over Time[J]. Am J Crit Care, 2021, 30(2):128-132. doi:10.4037/ajcc2021194. |
| [25] | WOO S, PARK S Y, KIM Y, et al. The Dynamics of Respiratory Microbiota during Mechanical Ventilation in Patients with Pneumonia[J]. J Clin Med, 2020, 9(3):638. doi:10.3390/jcm9030638. |
| [26] | LIU C, WU K, SUN T, et al. Effect of invasive mechanical ventilation on the diversity of the pulmonary microbiota[J]. Crit Care, 2022, 26(1):252. doi:10.1186/s13054-022-04126-6. |
| [27] | DE CASTILHOS J, ZAMIR E, HIPPCHEN T, et al. Severe dysbiosis and specific haemophilus and neisseria signatures as hallmarks of the oropharyngeal microbiome in critically ill coronavirus disease 2019 (COVID-19) Patients[J]. Clin Infect Dis, 2022, 75(1):e1063-e1071. doi:10.1093/cid/ciab902. |
| [28] | LI W, GAO M, YU J. Rising prevalence and drug resistance of Corynebacterium striatum in lower respiratory tract infections[J]. Front Cell Infect Microbiol, 2024, 14:1526312. doi:10.3389/fcimb.2024.1526312. |
| [29] | HARDING C M, HENNON S W, FELDMAN M F. Uncovering the mechanisms of Acinetobacter baumannii virulence[J]. Nat Rev Microbiol, 2018, 16(2):91-102. doi:10.1038/nrmicro.2017.148. |
| [30] | ZHAO J, HUANG Y, LI J, et al. In vitro antibacterial activity and resistance prevention of antimicrobial combinations for dihydropteroate synthase-carrying stenotrophomonas maltophilia[J]. Infect Drug Resist, 2022, 15:3039-3046. doi:10.2147/IDR.S368338. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||